"
User contributions
From 2009.igem.org
(Latest | Earliest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 03:55, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 02:20, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Démarche expérimentale)
- 02:19, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Démarche expérimentale)
- 02:18, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 02:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Objectif)
- 02:15, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Objectif)
- 02:14, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Contexte)
- 02:13, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Le Ciblage cellulaire)
- 02:02, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Le vecteur tissulaire)
- 01:35, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats [1,2])
- 01:09, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats)
- 01:01, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Plasmide antitumoral)
- 00:25, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats)
- 00:19, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Plasmide antitumoral)
- 23:54, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion)
- 23:39, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Tissulaire (→Conclusion)
- 23:34, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Tissulaire (→Conclusion)
- 22:55, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion)
- 22:37, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion1Fr (→Conclusion) (top)
- 22:33, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept3Fr (→L’encapsidation au sein du vecteur cellulaire [1,2,3,4,5,6])
- 22:19, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Equipe (→L’équipe)
- 22:14, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 22:04, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2 (→The cell vector deliverance in the target organ [1,2,8])
- 22:01, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2 (→The cell vector: The lambda phage [1,2])
- 21:57, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1 (→To summarize…)
- 21:54, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1 (→Cell wall and tissue vector envelope)
- 21:49, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept (→The Double Vector System)
- 21:40, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/HomeEn (→The "DVS" Project)
- 21:24, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Remerciement (→Les étudiants)
- 21:12, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Les tissus cibles du DVS [6,7])
- 21:10, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Paroi cellulaire et enveloppe du vecteur tissulaire)
- 21:08, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Mécanisme de détournement du système immunitaire)
- 20:56, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion1 (→Conclusion)
- 20:52, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Gene therapies (→Gene therapy [1])
- 20:48, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Current therapies (→Current therapies)
- 19:22, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→La bio-terreur)
- 19:13, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Libération accidentelle)
- 19:10, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:05, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:05, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:04, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:01, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Avant Propos)
- 18:58, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Avant Propos)
- 18:54, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Formulaire pour les juges)
- 15:18, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion1 (→Conclusion)
- 13:10, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:08, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:06, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:05, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:02, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
(Latest | Earliest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
